-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...

-The Times of India NEW DELHI: Top selling medicine brands for stress, hypertension, HIV, pain and pneumonia may soon become cheaper. The drug price regulator National Pharmaceutical Pricing Authority (NPPA) is set to bring in at least 100 new drugs under price control to include combinations, dosages and strengths that are commonly prescribed by doctors and sold by pharmacists. For instance, currently only one strength of Paracetamol is under price control, whereas...

-The Indian Express The era of globalised markets is also an era of globalised sovereignties. Nation states must constantly sync their policies with global constituencies of policies and citizens. At times, domestic disharmony is the price nation states may be required and willing to pay. The case in point here is the proposed review of the intellectual property rights (IPR) policy, particularly those clauses that are related to pharmaceutical patent policy....

-Livemint The petition challenged NPPA's decision of withdrawing its internal guideline to set prices of non-Essential drugs New Delhi: The Supreme Court on Monday refused to entertain a petition challenging a decision by the country's drug price regulator to withdraw its internal guideline to set prices of non-Essential drugs. Earlier this year, the National Pharmaceutical Pricing Authority (NPPA) issued a guideline empowering itself to cap the prices of 108 non-Essential drugs, attracting...

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...